logo
logo

Ribon Therapeutics Announces Acquisition Of Pre-Clinical Cd38 Program By Boehringer Ingelheim

Nov 29, 2022•over 2 years ago

Acquiring Company

Ribon Therapeutics, Inc.

Acquired Company

CD38 Program

Cambridge

Description

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the acquisition of its CD38 program with Boehringer Ingelheim. This includes a small molecule inhibitor designed to modulate intra- and extracellular CD38 activity, potentially restoring immune function in various diseases, as well as corresponding patents and other proprietary information. Boehringer Ingelheim aims to develop novel therapies based on Ribon’s CD38 program to transform the lives of patients with immunological and fibrotic diseases.

Company Information

Company

Ribon Therapeutics, Inc.

Location

Cambridgepark Drive

Cambridge, Maryland, United States

About

Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Related People

Matthew hidden

Zachary hidden

Jessica hidden